In conclusion, this study has shown for the first time how assessment of hypermethylation of two targets, the FAM19A4 and mir124‐2 promoters, can aid in the diagnosis of OSCC and, more importantly, identify those patients affected by OPMDs at risk of cancer progression. Here, TAFA4 is linked to cancer.